



Contents lists available at ScienceDirect

## Food and Chemical Toxicology

journal homepage: [www.elsevier.com/locate/foodchemtox](http://www.elsevier.com/locate/foodchemtox)

## *Alpinia pricei* Hayata rhizome extracts have suppressive and preventive potencies against hypercholesterolemia

N.W. Chang<sup>a,\*</sup>, C.T. Wu<sup>b</sup>, S.Y. Wang<sup>c</sup>, R.J. Pei<sup>d</sup>, C.F. Lin<sup>a,\*\*</sup><sup>a</sup> Departments of Biochemistry, College of Medicine, China Medical University, 91 Hsueh-Shih Road, Taichung 404, Taichung, Taiwan, ROC<sup>b</sup> Department of Surgery, Feng-Yuan Hospital, Department of Health, Executive Yuan, Taichung, Taiwan, ROC<sup>c</sup> Department of Forestry, National Chung-Hsing University, Taichung, Taiwan, ROC<sup>d</sup> Department of Pathology, Jen-Ai Hospital, Tali, Taichung County, Taiwan, ROC

## ARTICLE INFO

## Article history:

Received 15 June 2009

Accepted 25 May 2010

Available online xxx

## Keywords:

*Alpinia pricei* Hayata

Hypercholesterolemia

Alanine aminotransferase

Peroxisome proliferator activated receptor gamma

## ABSTRACT

The aim of this study was to investigate the effects of 70% ethanol extracts of *Alpinia pricei* (APE) on lipid profiles and lipid peroxidation. Syrian hamsters were fed a chow-based hypercholesterolemic diet (HCD) for 2 weeks to induce hypercholesterolemia (>250 mg/dl). To evaluate the potency of APE in suppressing hypercholesterolemia, hamsters were then fed HCD plus a high dose (500 mg/kg body weight) or a low dose (250 mg/kg body weight) of APE, or only HCD for another 4 weeks. We found that hypercholesterolemic hamsters fed a high dose of APE had lower serum total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) levels, lower thiobarbituric acid reactive substances (TBARS) and alanine aminotransferase (ALT) activities, lower atherogenic indices (LDL-C/HDL-C and TC/HDL-C ratios), and lower hepatic protein expression of peroxisome proliferator activated receptor gamma (PPAR $\gamma$ ) than hamsters fed a HCD diet. In addition, we also determined the preventive effects of APE on hamsters fed a HCD for 6 weeks. The hypocholesterolemic effects were also found in hamsters co-fed a high dose of APE and HCD for 6 weeks. These results suggest that APE has both suppressive and preventive potencies against hypercholesterolemia and has the potency to protect against lipid peroxidation.

© 2010 Published by Elsevier Ltd.

### 1. Introduction

*Alpinia pricei* Hayata (Zingiberaceae) is a perennial rhizomatous herb indigenous to Taiwan. The leaves of *A. pricei* are used to make glutinous rice dumplings and the aromatic rhizome of *A. pricei* is thought to dispel abdominal distension and increase stomach secretion and peristalsis. Many *Alpinia* plants are considered medicinal herbs and have been reported to possess antioxidant (Shi et al., 2006), anti-inflammatory (Israf et al., 2007; Lin et al., 2009), anticancer (Ali et al., 2001; Lee and Houghton, 2005; Yang et al., 2008), immunostimulating (Bendjeddou et al., 2003), hepatoprotective (Kadota et al., 2003) and antinociceptive (Arambewela et al., 2004) activities.

Atherosclerosis is a disease involving both hypercholesterolemia and inflammation. Atherosclerosis is initiated by elevated levels of low-density lipoprotein (LDL) and other proatherogenic

lipoproteins. In the presence of oxidative stress, LDL becomes the highly reactive form of oxidized LDL after lipid oxidative modification (Chisolm and Steinberg, 2000). Oxidized LDL and/or oxidized lipids can participate in many of the immunologic and inflammatory processes in the complex progression of the atherosclerotic lesion (Steinberg, 2005). In addition to decreasing LDL cholesterol levels, oxidized LDL should be also taken into consideration for preventing cardiovascular events in hypercholesterolemia with drug therapy. Therefore, oxidized LDL is considered as a marker for hypercholesterolemia. Peroxisome proliferator activated receptor gamma (PPAR $\gamma$ ), a member of the nuclear receptor superfamily of ligand activated transcription factors, is a key regulator of adipogenesis and lipid metabolism (Plutzky, 2000). PPAR $\gamma$  has been shown to regulate monocyte/macrophage gene expression (Nagy et al., 1998) and to promote monocyte differentiation and uptake of oxidized LDL through transcriptional induction of the scavenger receptor CD36 (Tontonoz et al., 1998). Current medical treatments of hyperlipidemia involve the use of statins, fibrates, and resins (Knopp et al., 2008). In addition, many medicinal plants and their active metabolites are considered potential hypolipidemic agents, such as curcumin derived from *Curcuma longa* (Zingiberaceae) (Ramírez-Tortosa et al., 1999; Olszanecki et al., 2005). Extensive research on Zingiberaceae plants has shown that *Alpinia zerumbet* (Lin et al., 2008) and *Alpinia officinarum* (Shin et al., 2004) have

**Abbreviations:** ALT, alanine aminotransferase; APE, *Alpinia pricei* extracts; HCD, chow-based hypercholesterolemic diet; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; PPAR $\gamma$ , peroxisome proliferator activated receptor gamma; TBARS, thiobarbituric acid reactive substances.

\* Corresponding author. Tel.: +886 4 22053366x2151; fax: +886 4 22053764.

\*\* Corresponding author. Tel.: +886 4 22053366x2158; fax: +886 4 22053764.

E-mail addresses: [nwchang@mail.cmu.edu.tw](mailto:nwchang@mail.cmu.edu.tw) (N.W. Chang), [cflin@mail.cmu.edu.tw](mailto:cflin@mail.cmu.edu.tw) (C.F. Lin).

hypolipidemic activities. The effects of *A. pricei* Hayata on lipid metabolism, however, have not been studied.

Animal models of diet-induced hypercholesterolemia are useful for assessing the effects of drugs (Fernandez et al., 1999). Hamsters in particular are extensively used for studying the effects of diet or drug on plasma lipid levels and the mechanisms involved because hamster models of disease present characteristics that resemble those in humans (Fernandez et al., 1999; Sawada et al., 2002; Wilson et al., 1999, 2006). This study was designed to assess the preventive and therapeutic efficacy of 70% ethanol extracts of *A. pricei* Hayata (APE) in hypercholesterolemic hamsters. The serum lipid and lipoprotein profiles, thiobarbituric acid reactive substances (TBARS), and oxidized LDL were measured as markers of hypercholesterolemia. Moreover, the liver lipids, PPAR $\gamma$  protein expression, and serum alanine aminotransferase (ALT) activity were also examined to evaluate hepatic response to APE.

## 2. Materials and methods

### 2.1. Plant material and extract preparation

The rhizomes of *A. pricei* Hayata were collected from Ping-tung County in southern Taiwan in March, 2007 and were identified by Dr. Yen-Hsueh Tseng (National Chung-Hsin University). A voucher specimen was deposited in the herbarium of the same university. The air-dried rhizomes (2 kg) of *A. pricei* were extracted with 10 L 70% ethanol at room temperature. The total crude extracts were evaporated in a vacuum to yield the ethanol extracts (166 g).

### 2.2. Identification and quantification of major compounds in APE

The 70% ethanol extracts of *A. pricei* (APE) were separated by semi-preparative high performance liquid chromatography (HPLC). A Luna silica column (250  $\times$  10 mm, Phenomenex Co.) was employed in this study with two solvents systems, H<sub>2</sub>O (A) and 100% acetonitrile (B). The gradient elution profile was as follows: 0–3 min, 80% A–B; 3–60 min, 80–0% A–B (linear gradient); 60–80 min 0% A–B; the flow rate was 2.5 mL/min and the detector wavelength was set at 280 nm. The major three compounds (Fig. 1A) in the APE were obtained at retention times of 32.5 min (1), 37.0 min (2), and 46.7 min (3). According to HPLC analysis, the amounts of compounds 1, 2, and 3 in APE were 1.1%, 8.9%, and 5.7%, respectively. The structures of compounds 1–3 were then elucidated using spectroscopic analyses. UV spectra of test compounds were recorded with a Jasco V-550 spectrometer and IR spectra obtained from a Bio-Rad FTS-40 spectrophotometer. Electron-impact mass spectrometry (EIMS) and high resolution electron-impact mass spectrometry (HREIMS) data were collected with a Finnigan MAT-958 mass spectrometer and NMR spectra recorded with Bruker Avance 500 and 300 MHz FT-NMR spectrometers, at 500 MHz (<sup>1</sup>H) and 75 MHz (<sup>13</sup>C). According to the mass and NMR analyses, compounds 1–3 were identified as (1) desmethoxyyangonin (Dharmaratne et al., 2002), (2) cardamonin (Ngo and Brown, 1998), and (3) flavokawain B (Dharmaratne et al., 2002) (Fig. 1B).

### 2.3. Animals and treatments

Seven-week-old male Syrian hamsters (*Mesocricetus auratus*) were purchased from the National Laboratory Animal Center. The hamsters were handled in accordance with the animal care and use guidelines of the China Medical University and the study protocol was approved by the Institutional Animal Care Use Committee. Male hamsters rather than female hamsters were used because previous data (Wilson et al., 1999) indicate that male hamsters are more likely to develop early aortic atherosclerosis compared to age-matched premenopausal female hamsters. The experiments were carried out under controlled conditions with a 12-h light/dark cycle. Hamsters were allowed access to drinking water and diet ad libitum during the experimental periods. All hamsters were weighed every week.

To examine the hypocholesterolemic potency, two doses of APE, 250 or 500 mg/kg body weight, were used in our study according to the previous trials (Chou et al., 2009; Lin et al., 2009). In the study by Chou et al., a chow diet with an APE (1500 mg/kg body weight) was used to assess the effects of APE on metabolic syndrome. In the study by Lin et al., flavokawain B (200 mg/kg body weight) extracted from *A. pricei* was administered to ICR mice by intraperitoneal injection. The dose intake of flavokawain B (200 mg/kg body weight) was equivalent to 3508 mg APE/kg body weight. We considered a mouse body weight is only one fourth of a hamster, thus we selected 250 and 500 mg APE/kg body weight in this study.

A hypercholesterolemic hamster model was established according to the method of Wilson (Wilson et al., 2006). A chow-based hypercholesterolemic diet (HCD) contained 89.9% (w/w) murine powdered chow diet (Fwosol Industry Co., Taiwan), 10% coconut oil (Chung Shing Chemicals Co., Taiwan), and 0.1% cholesterol (Sigma-aldrich, St. Louis, MO, USA). There are four steps for a chow-based hypercholesterolemic diet (HCD) preparation as the followings: (1) chow diet was ground into powder and weighed (89.9%, w/w, S) for HCD preparation, (2) a small amount of S (S1) was mixed with 0.1% (w/w) cholesterol powder (C), (3) coconut oil (10%, w/w, O) was added progressively and mixed with previous mixture (C + S1), and (4) the remaining powdered chow diet (S – S1) was mixed progressively with C + S1 + O mixture. The HAP diet was prepared by mixing 0.86% APE (equivalent to 500 mg APE/kg body weight) with 10% coconut oil, 0.1% cholesterol, and 89.04% powdered chow diet. The LAP diet was prepared by mixing 0.43% APE (equivalent to 250 mg APE/kg body weight) with 10% coconut oil, 0.1% cholesterol, and 89.47% powdered chow diet. To keep the diet stability, all diets were stored at 4°C before use. Each hamster was housed individually in a polycarbonate cage. Powdered diets were given to the hamsters in stainless steel containers and were refreshed every day.

### 2.4. Experimental protocol

The experimental protocol is shown in Fig. 2. Hamsters ( $n = 40$ ) were randomly assigned to five groups of eight hamsters in each and fed the respective treatment diets. Hamsters in group 1 served as controls and received a powdered chow diet for 6 weeks. Hamsters in group 2 (HCD) received HCD for 6 weeks. Hamsters in group 3 (4HAP) received HCD for 2 weeks, followed by a HAP diet for 4 weeks. Hamsters in group 4 (4LAP) received HCD for 2 weeks, followed by a LAP diet for 4 weeks. Hamsters in group 5 (GHAP) received a HAP diet for 6 weeks. The experimental design in groups 3 and 4 was used to evaluate the suppressive effects of APE on hypercholesterolemia and that in group 5 was aimed to assess the preventive effects of APE on a high cholesterol diet. This study has been done under Good Laboratory Practice (GLP).





Fig. 1. (A) The HPLC chromatogram of the 70% ethanol extracts of *Alpinia pricei*. Three phenolic compounds (1–3) were isolated. (B) The structures of compounds 1–3. According to the mass and NMR analyses, compounds 1–3 were identified as desmethoxyyangonin (1), cardamonin (2), and flavokawain B (3).



**Fig. 2.** Experimental protocol. □, chow diet; ■, high cholesterol diet (HCD); ▨, high dose *Alpinia pricei* extracts (500 mg/kg body weight); ▩, low dose *Alpinia pricei* extracts (250 mg/kg body weight).

174 2.5. Blood sample collection and analyses

175 All of the hamsters were sacrificed after an overnight fast of 12 h under CO<sub>2</sub>  
 176 anesthesia at the end of 6 weeks. Blood was centrifuged (365 × g) for 20 min. The  
 177 serum was stored at 4 °C before analysis. So far there is no universal anticoagulant  
 178 that could be used for evaluation of several laboratory parameters in a sample from  
 179 a single test tube. The reason for using serum but not plasma is based on different  
 180 requirement of analytic method. For example, anticoagulant EDTA is unsuitable for  
 181 lipoprotein lipase activity determination because lipoprotein lipase uses metal ion  
 182 as coenzyme. Therefore, we collect serum for all analysis in this study. Serum total  
 183 cholesterol, low-density lipoprotein-cholesterol (LDL-C), high density lipoprotein-  
 184 cholesterol (HDL-C), and triacylglycerol (TG) were determined by commercial kit  
 185 enzymatic methods (DiaSys Diagnostic Systems GmbH, Holzheim, Germany). We  
 186 used precipitation reagent for *in vitro* determination of LDL cholesterol with the  
 187 CHOP-PAP method by photometric system. LDL was precipitated by addition of  
 188 heparin. HDL and VLDL remain in the supernatant after centrifugation and were  
 189 measured enzymatically by the CHOD-PAP method. The concentration of LDL choles-  
 190 terol was calculated as the difference between total cholesterol and cholesterol  
 191 in the supernatant (VLDL-cholesterol and HDL-cholesterol). The commercial kits  
 192 including LDL Precipant (Ecoline®, Dia Sys Diagnostic System GmbH, Germany)  
 193 and cholesterol FS (Dia Sys Diagnostic System GmbH, Germany). Cholesterol N Cal-  
 194 ibrator was the reference standard (Diaichi Pure Chemicals Co., LTD, Tokyo, Japan).  
 195 HDL-cholesterol was measured spectrophotometrically following precipitation  
 196 with phosphotungstic acid and magnesium ions to remove LDL and VLDL. Centrifug-  
 197 ation leaved only the HDL in the supernatant. HDL cholesterol content was deter-  
 198 mined enzymatically using Ecoline S+ cholesterol kits. The commercial kits  
 199 including HDL Precipant (Ecoline®, Dia Sys Diagnostic System GmbH, Germany)  
 200 and cholesterol FS (Dia Sys Diagnostic System GmbH, Germany). In addition, the  
 201 concentration of non-HDL-cholesterol was calculated as the difference between total  
 202 cholesterol and HDL-cholesterol. Therefore, LDL cholesterol concentrations are  
 203 not equal to non-HDL cholesterol concentrations. Serum lipoprotein lipase and ala-  
 204 nine aminotransferase (ALT) activities were determined enzymatically utilizing  
 205 Randox kits (Randox Laboratories Ltd. Co. Antrim, UK). Serum thiobarbituric acid  
 206 reactive substances (TBARS) were determined using a ZeptoMetrix Kit (ZeptoMetrix  
 207 Corporation, buffalo, NY, USA). Serum oxidized LDL concentrations were measured  
 208 spectrophotometrically using an ELISA kit (Mercodia AB, Uppsala, Sweden) as pre-  
 209 viously described (Kopprasch et al., 2002).

210 2.6. Hepatic lipid measurement

211 The liver was excised and then divided into two portions. One portion was used  
 212 to determine the hepatic cholesterol and triacylglycerol concentrations as previ-  
 213 ously described (Chang et al., 2004). The second portion was used to analyze PPARγ  
 214 protein by Western blotting.

215 2.7. Western blot analysis

216 The liver was homogenized in a sucrose-HEPES buffer containing 0.5% Nonidet  
 217 P40, protease inhibitors, and dithiothreitol according to the method of Kim et al.  
 218 (2007). Then, the nuclear proteins were extracted (Kim et al., 2007) and the protein  
 219 concentration was determined using a protein assay kit (Pierce Biotechnology,  
 220 Rockford, USA), with bovine serum albumin as the standard. Samples were resolved  
 221 by SDS-PAGE, transferred to nitrocellulose membrane and probed with antibodies  
 222 against PPARγ (1:1000, Santa Cruz Biotechnology Inc., California, USA) and β-actin

(1:2000, Santa Cruz Biotechnology Inc., California, USA). Signals were developed  
 using SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology,  
 Rockford, USA).


226 2.8. Statistical analysis

227 All data were analyzed using SPSS 15.0 for windows. All results are shown as  
 228 mean ± SD. Group is the only factor for evaluation and values of total cholesterol,  
 229 LDL-C, HDL-C, or TG are the outcomes. Therefore, one way analysis of variance  
 230 (ANOVA) is used in this study. Significant differences between groups were  
 231 analyzed using ANOVA followed by multiple comparison tests. A *p*-value of less  
 232 than 0.05 was considered statistically significant.

233 3. Results

234 3.1. Effects of APE on lipid profiles and atherogenic indices

235 There were no significant differences in dietary intake or body  
 236 weight of hamsters (data not shown). Our preliminary studies  
 237 showed that hamsters fed HCD for 2 weeks had significantly higher  
 238 serum total cholesterol (275.2 ± 5.4 vs. 117.5 ± 12.7 mg/dl), LDL-C



**Fig. 3.** Serum lipid levels in hamsters fed low dose (250 mg/kg body weight) or high dose (500 mg/kg body weight) *Alpinia pricei* extracts. Values are means ± SD. <sup>a</sup>Significantly different from control (*P* < 0.05). <sup>b</sup>Significantly different from HCD (*P* < 0.05). <sup>c</sup>Significantly different from 4HAP (*P* < 0.05). Groups are described in Fig. 2.

(190.6 ± 11.3 vs. 80.5 ± 4.8 mg/dl), HDL-C (45.5 ± 6.3 vs. 26.0 ± 5.7 mg/dl), and TG (157.7 ± 37.4 vs. 63.3 ± 9.7 mg/dl) levels than hamsters fed a control chow diet. Therefore, the effects of APE on lipid levels in hypercholesterolemic hamsters were examined after a 2-week HCD induction.

Fig. 3 shows the serum lipids levels in hypercholesterolemic hamsters fed low or high doses APE. The levels of serum TG in the HCD (106%,  $p = 0.026$ ), 4LAP (213%,  $p < 0.001$ ) and 6HAP (156%,  $p = 0.001$ ) groups were significantly higher than those in the control group, while the TG level in the 4HAP group did not differ significantly from that in the control group or that in the HCD group ( $p = 0.718$ ). Serum TG level in the 4LAP group, however, was significantly higher than that in the HCD group (52%,  $p = 0.025$ ) and in the 4HAP group (88%,  $p = 0.001$ ).




Fig. 4. Serum LDL-C/HDL-C ratios and TC/HDL-C ratios in hamsters. TC: total cholesterol. Values are means ± SD. <sup>a</sup>Significantly different from HCD ( $p < 0.01$ ). <sup>b</sup>Significantly different from group 1 ( $p < 0.01$ ). Groups are described in Fig. 2.

Feeding hamsters with HCD for 6 weeks resulted in a 2.4-fold increase in serum total cholesterol (Fig. 3). Serum total cholesterol and LDL-C levels significantly decreased in animals after receiving high doses of 4HAP or 6HAP. However, LDL-C levels remained unchanged after feeding with low-dose APE (4LAP). HDL-C levels were significantly higher in the 4HAP and 6HAP groups than in the control group ( $p < 0.05$ ). There was no significant difference in HDL-C levels between the 4LAP group and control group. Also, no significant differences were observed between HCD and 4HAP groups. Serum HDL-C levels after treatment in the 6HAP group were 26% higher than those in the HCD group ( $p < 0.05$ ).

In addition, we found that animals fed high-dose APE (4HAP or 6HAP) had lower LDL-C/HDL-C and TC/HDL-C ratios than animals in the HCD group (Fig. 4,  $p < 0.01$ ). There was no significant difference in ratios between 4LAP and HCD groups.

### 3.2. Effects of APE on serum TBARS, lipoprotein lipase, and ALT activities and oxidized-LDL levels

According to the study of Verhagen et al. (2003), 10 basic requirements for a scientific paper reporting antioxidant, antimutagenic or anticarcinogenic potential of test substances in *in vitro* experiments and animal studies *in vivo* were suggested. In the valid and invalid test systems section, they mentioned that the measurement of lipid peroxidation *in vivo* should use TBARS (Griffiths et al., 2002). Serum TBARS activity and oxidized LDL level were used to evaluate lipid peroxidation which is associated with atherosclerosis. No significant differences in TBARS activity were observed between HCD and control groups ( $p = 0.413$ , Fig. 5A). When compared with HCD, 4HAP and 6HAP significantly decreased TBARS activity ( $p < 0.01$ ), but this effect was not observed after treatment with low-dose APE (4LAP). There were significant decreases in oxidized LDL between the 4HAP, 6HAP and control groups ( $p < 0.05$ , Fig. 5C). No significant differences in serum oxidized LDL levels between hamsters fed the HCD (group 2) and those fed HCD supplemented with high dose of APE (group 3).





Fig. 5. Serum TBARS (A), lipoprotein lipase (B), and alanine aminotransferase (C) activities and oxidized LDL levels (D) in hamsters. Values are means ± SD. <sup>a</sup>Significantly different from group 1 ( $p < 0.05$ ). <sup>b</sup>Significantly different from group 2 ( $p < 0.05$ ). <sup>c</sup>Significantly different from group 3 ( $p < 0.01$ ). Group 1: control; Group 2: HCD; Group 3: 4HAP; Group 4: 4LAP; Group 5: 6HAP. Groups are described in Fig. 2.


287 Factors such as malnutrition, physical inactivity, uremic toxins,  
288 and inflammation are known to influence the activity of lipopro-  
289 tein lipase, an important enzyme in metabolism of blood lipids.  
290 Through the action of lipoprotein lipase, triglycerides in plasma  
291 lipoproteins are hydrolyzed to fatty acids and monoglycerides, a  
292 prerequisite for their utilization in tissues. Lipoprotein lipase is  
293 synthesized mainly in adipocytes and myocytes, but is secreted  
294 from these cells and transported to the luminal side of the vascular  
295 endothelium. Disturbances in the activity of lipoprotein lipase can  
296 be coupled to proatherogenic lipid profiles including elevated  
297 levels of plasma triglycerides and low levels of HDL-cholesterol  
298 Q2 (Twickler et al., 2005; Mead and Ramji, 2002). Therefore, the lipo-  
299 protein lipase activity, which involved the changes of plasma TG  
300 levels, was determined in our study. No significant differences in  
301 lipoprotein lipase activity were observed between groups  
302 ( $p > 0.05$ , Fig. 5B). Serum ALT activity was used to detect liver func-  
303 tion. ALT activity was significantly lower in animals after high- or  
304 low-dose APE treatment than in animals fed only a high cholesterol  
305 diet ( $p < 0.05$ , Fig. 5D).

306 3.3. Effects of APE on hepatic TG and cholesterol levels and on hepatic  
307 PPAR $\gamma$  expression

308 Liver weight and liver weight/body weight ratio were measured  
309 after 6-week treatment. The liver weights are  $3.20 \pm 0.48$  g in control  
310 group (a chow-based diet),  $4.54 \pm 0.46$  g in HCD group,  $4.23 \pm$   
311  $0.29$  g in 4HAP group,  $4.54 \pm 0.47$  g in 4LAP group,  $4.74 \pm 0.56$  g in  
312 6HAP group. The ratios of liver weight/body weight are  
313  $0.0308 \pm 0.0021$  in control group,  $0.0402 \pm 0.0015$  in HCD group,  
314  $0.0393 \pm 0.0015$  in 4HAP group,  $0.0414 \pm 0.0019$  in 4LAP group,  
315  $0.0421 \pm 0.0024$  in 6HAP group. The liver weight and the liver  
316 weight/body weight ratio were significantly higher in animals treated  
317 with HCD-based diets (HCD, 4HAP, 4LAP, and 6HAP) than in  
318 animals fed only a chow-based diet. No differences in liver  
319 weight/body weight ratio were observed between hamsters fed the  
320 HCD and those fed HCD supplemented with HAP or LAP. Hepatic  
321 TG level in 4LAP group was significantly 80% higher than that in HCD  
322 group ( $p < 0.05$ , Fig. 6). Dietary administration of cholesterol signifi-  
323 cantly increased liver cholesterol levels in groups HCD (3.05-fold),  
324 4HAP (3.31-fold), 4LAP (3.14-fold), and 6HAP (3.15-fold) when com-  
325 pared with control group ( $p < 0.001$ , Fig. 6). However, liver chole-  
326 sterol levels in all APE feeding groups were not significantly



327 **Fig. 6.** Liver lipid levels in hamsters fed a low dose (250 mg/kg body weight) or a  
328 high dose (500 mg/kg body weight) *Alpinia pricei* extracts. Values are means  $\pm$  SD.  
329 <sup>a</sup>Significantly different from HCD ( $p < 0.05$ ). <sup>b</sup>Significantly different from control  
330 ( $p < 0.001$ ). Groups are described in Fig. 2.



331 **Fig. 7.** The expression of PPAR $\gamma$  in hamsters. Livers were homogenized after  
332 6 weeks and nuclear proteins isolated for Western analysis. Results represent four  
333 independent experiments. Densitometric analysis and normalization to  $\beta$ -actin are  
334 expressed as mean  $\pm$  SD. <sup>a</sup>Significantly different from HCD ( $p < 0.01$ ). <sup>b</sup>Significantly  
335 different from 4HAP ( $p < 0.05$ ). Groups are described in Fig. 2.

336 different from the HCD group. In addition, the protein expression of  
337 PPAR $\gamma$ , which related the formation of atherosclerosis, was exam-  
338 ined. We found the expression of PPAR $\gamma$  in the 4HAP group was the  
339 lowest among the five groups and was 54% and 51% lower than that  
340 in the HCD group ( $p < 0.01$ ) and the 4LAP group ( $p < 0.05$ , Fig. 7).  
341

342 **4. Discussion**

343 Risk of coronary heart disease is positively associated with total  
344 cholesterol and LDL-C and inversely associated with HDL-C  
345 (Knopp et al., 2008). According to the study by Wilson et al.  
346 (2006), 100 hamsters were fed a chow-based hypercholesterolem-  
347 ic diet (HCD) containing 10% coconut oil and 0.1% cholesterol  
348 for 2 week. Dietary treatments were fed for 8 or 12 weeks. Wilson  
349 et al. indicated that plasma HDL-C concentrations were  
350  $68.3 \pm 3.38$  mg/dl after an 8-week and  $94.4 \pm 17.1$  mg/dl after a  
351 12-week HCD feeding. We used the similar HCD formula (89.9%  
352 (w/w) murine powdered chow diet, 10% coconut oil, and 0.1% cho-  
353 lesterol) to induce hypercholesterolemia in hamsters and found  
354 HDL-C concentration was  $45.5 \pm 6.3$  mg/dl after a 6-week HCD  
355 feeding. In this study, we found that high-dose APE (500 mg/  
356 kg body weight) showed a stronger effect in lowering serum TC  
357 and LDL-C levels than low-dose APE (250 mg/kg body weight)  
358 (Fig. 3) in hypercholesterolemic hamsters. In the 4HAP group, ser-  
359 um TC level was 22% lower and serum LDL-C level was 28% lower  
360 than those levels in the HCD group, but the TC and LDL-C levels  
361 remained unchanged in the 4LAP group. The LDL-C/HDL-C and  
362 TC/HDL-C ratios were 44% and 33% lower in the 4HAP group than  
363 those ratios in the HCD group (Fig. 4). Increased LDL-C/HDL-C and  
364 TC/HDL-C ratios are associated with high risk for the development  
365 of cardiovascular disease and atherosclerosis (Castelli, 1992). The  
366 hypocholesterolemic effects were also found in hamsters co-fed a  
367 high dose of APE and HCD for 6 weeks; the atherogenic indices  
368 (LDL-C/HDL-C and TC/HDL-C ratios) in the 6HAP group were 44%  
369 and 30% lower than those in the HCD group (Fig. 4). The results  
370 indicate that high-dose APE has both preventive and suppressive  
371 effects on hypercholesterolemia.

372 *Alpinia* species has been found to have antioxidant activity  
373 (Chen et al., 2008). According to HPLC and spectroscopic analyses,  
374 we found that the main compositions of ethanol extracts of *A. pricei*  
375 Hayata were desmethoxyyangonin (1.1%), cardamonin (8.9%), and  
376

flavokawain B (5.7%). Cardamonin (2',4'-dihydroxy-6'-methoxy-chalcone) is a potential anti-inflammatory drug that targets the NF- $\kappa$ B pathway (Israf et al., 2007). The chalcone moiety of cardamonin has anti-oxidation and free-radical scavenging activity (Bors et al., 1990). In our study, the activity of TBARS was 37% lower in the 4HAP group and 21% lower in the 6HAP group than in the HCD group (Fig. 5A). A decrease in TBARS activity is important in preventing lipid peroxidation which is associated with atherosclerosis (Korantzopoulos et al., 2003). Lipid peroxides frequently decompose to reactive aldehydes like malondialdehyde and 4-hydroxynonenal that react with nucleic acids, proteins and lipids, causing tissue and organ damage (Slatter et al., 2000). Oxidative modification of lipids, in particular LDL, is suggested to play a key role in atherosclerosis (Chisolm and Steinberg, 2000). We found that the levels of serum oxidized LDL in the 4HAP and 6HAP groups were lower than in the HCD group, although there was no significant difference in level between the two groups. Our interpretation is that APE delays the start of lipid oxidation in LDL by reducing the formation of TBARS through its anti-oxidation and free-radical scavenging activity (Bedwell et al., 1989; Esterbauer et al., 1987). These results indicate that high-dose APE has the potency to protect against lipid peroxidation. We did not determine how APE delays the start of lipid oxidation in LDL but we directly determined the serum oxidized LDL level. The reason is that the blood volume per hamster is not enough to do various biochemical analysis and to ultracentrifuge for LDL preparation. In addition, Dr. Yen et al., the other team group who is also studying *A. pricei* Hayata, have found that APE possessed inhibitory effect on the oxidative modification of LDL induced by Cu<sup>2+</sup> (unpublished data).

In addition, the expression of hepatic PPAR $\gamma$  in the 4HAP group was significantly lower than that in the HCD group (Fig. 7). A decrease in PPAR $\gamma$  expression in the 4HAP group may be due to APE-induced reduction in lipid peroxidation. Several endogenous oxidized lipids have been identified as ligands of PPAR $\gamma$  (Tontonoz et al., 1998; Nagy et al., 1998). Stimulation of PPAR $\gamma$  activity by oxidized lipids enhances the transcription of CD36, leading to further uptake of oxidized LDL and differentiation of monocytes into foam cells (Tontonoz et al., 1998; Nagy et al., 1998). Oxidized lipids promote macrophage aggregation and up-regulate the process of atherosclerosis by enhancing the expression of PPAR $\gamma$  (Schild et al., 2002). Therefore, one possible mechanism for the decrease in the expression of PPAR $\gamma$  in the HAP group could be explained by reducing endogenous oxidized lipids. Oxidized LDL represented a variety of modification of both lipid and apolipoprotein B components by lipid peroxidation. Among lipid oxidation products of oxidized LDL, oxidized forms of linoleic and arachidonic acids, 9-hydroxyoctadecadienoic acid (9-HODE), 13-HODE, and 15-hydroxyicosatetraenoic acid (15-HETE), were efficient stimuli of PPAR $\gamma$ -mediated reporter gene transcription (Nagy et al. 1998). Another class of oxidized lipids is short-chain phosphatidylcholine (PC) formed by cleavage of a double bond in 18–20 carbon polyunsaturated acyl chains of the lipid (Itabe et al., 1994). In fact, more studies on the anti-atherosclerotic mechanism, changes in the early aortic atherosclerosis, and potential effects of APE on regulation of PPAR $\gamma$  expression should be examined in the future.

Increases in liver cholesterol level occurred in all animals that received a high cholesterol diet. No significant differences in liver cholesterol were observed between hamsters fed HCD or HCD supplemented with low- or high-dose APE. An increase in cholesterol accumulation in liver may be due to the HCD diets. In addition, ALT is an enzyme produced mainly in the liver. The release of the enzyme is thought to occur during damage of the liver, which results in an elevation of ALT in serum. Accordingly, it has been well accepted that when serum activity is measured, the enzyme, ALT, provides as a marker of hepatic diseases (Sherman, 1991; Iwaki

et al., 2007). ALT activity can be measured both in serum and in liver. However, in an animal study of liver fattening, Bogin et al. (1986) found that in the serum from fatty liver rats, there were significant changes in the level of ALT (+68.7%) when compared with normal rats. In contrast, the level of ALT was reduced (–23%) upon detected in the fatty liver (Bogin et al., 1986). Comparison the sensitivity of detected samples from serum with hepatic cells showed detection of ALT from serum is superior to liver cells (Bogin et al., 1986). Therefore, we used the serum samples for detection of ALT to reflect the dysfunction of liver in our animal model. In this study, serum ALT activity in hamsters fed HCD for 6 weeks was 64% higher than that in control animals. Notably, ALT levels in animals exposed to an APE-admixed HCD were significantly lower than those in hamsters fed HCD only (Fig. 5D) indicating that APE has the potency to protect liver function.

In conclusion, the present study demonstrates that APE causes a marked decrease in levels of TC, LDL-C, TBARS, ALT, and PPAR $\gamma$  protein expression as well as a marked reduction in LDL-C/HDL-C and TC/HDL-C ratios in hypercholesterolemic hamsters. These results suggest that APE has both suppressive and preventive potencies against hypercholesterolemia and has the potency to protect against lipid peroxidation. The APE-induced anti-atherosclerotic mechanism may be, at least in part, responsible for a decrease in the expression of PPAR $\gamma$  by reducing endogenous oxidized lipids.

#### Conflict of Interest

The authors declare that there are no conflicts of interest.

#### Acknowledgements

This work was supported by the China Medical University (Grants CMU95-035 and CMU95-094). We are very grateful to Jeffrey C. Conrad for his valuable comments regarding this manuscript.

#### References

- Ali, M.S., Banskota, A.H., Tezuka, Y., Saiki, I., Kadota, S., 2001. Antiproliferative activity of diarylheptanoids from the seeds of *Alpinia blepharocalyx*. *Biol. Pharm. Bull.* 24, 525–528.
- Arambewela, L.S., Arawwawala, L.D., Ratnasooriya, W.D., 2004. Antinociceptive activities of aqueous and ethanolic extracts of *Alpinia calcarata* rhizomes in rats. *J. Ethnopharmacol.* 95, 311–316.
- Bedwell, S., Dean, R.T., Jessup, W., 1989. The action of defined oxygen-centred free radicals on human low-density lipoprotein. *Biochem. J.* 6, 67–75.
- Bendjeddou, D., Lalaoui, K., Satta, D., 2003. Immunostimulating activity of the hot water-soluble polysaccharide extracts of *Anacyclus pyrethrum*, *Alpinia galangal*, and *Citrullus colocynthis*. *J. Ethnopharmacol.* 88, 155–160.
- Bogin, E., Avidar, Y., Merom, M., 1986. Biochemical changes in liver and blood during liver fattening in rats. *J. Clin. Chem. Clin. Biochem.* 24, 621–626.
- Bors, W., Heller, W., Michel, C., Saran, M., 1990. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. *Meth. Enzymol.* 186, 343–355.
- Castelli, W.P., 1992. Epidemiology of triglycerides: a view from Framingham. *Am. J. Cardiol.* 70, H3–H9.
- Chang, N.W., Wu, C.T., Chen, F.N., Huang, P.C., 2004. High polyunsaturated and monounsaturated fatty acids to saturated fatty acid ratio increases plasma very low density lipoprotein lipids and reduces the hepatic hypertriglyceridemic effect of dietary cholesterol in rats. *Nutr. Res.* 24, 73–83.
- Chen, I.N., Chang, C.C., Ng, C.C., Wang, C.Y., Shyu, Y.T., Chang, T.L., 2008. Antioxidant and antimicrobial activity of Zingiberaceae plants in Taiwan. *Plant Foods Hum. Nutr.* 63, 15–20.
- Chisolm, G.M., Steinberg, D., 2000. The oxidative modification hypothesis of atherogenesis: an overview. *Free Radic. Biol. Med.* 28, 1815–1826.
- Chou, Y.C., Wang, S.Y., Chen, G.C., Lin, Y.S., Chao, P.M., 2009. The functional assessment of *Alpinia pricei* on metabolic syndrome induced by sucrose-containing drinking water in mice. *Phytother. Res.* 23, 558–563.
- Dharmaratne, H.R., Nanayakkara, N.P., Khan, I.A., 2002. Kavalactones from *Piper methysticum*, and their <sup>13</sup>C NMR spectroscopic analyses. *Phytochemistry* 59, 429–433.
- Esterbauer, H., Jurgens, G., Quehenberger, O., Koller, E., 1987. Autoxidation of human low-density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. *J. Lipid Res.* 28, 495–509.

- 499 Fernandez, M.L., Wilson, T.A., Conde, K., Vergara-Jimenez, M., Nicolosi, R.J., 1999. Hamsters and guinea pigs differ in their plasma lipoprotein cholesterol  
500 distribution when fed diets varying in animal protein, soluble fiber, or  
501 cholesterol content. *J. Nutr.* 129, 1323–1332.
- 502 Griffiths, H.R., Moller, L., Bartosz, G., Bast, A., Bertoni-Freddari, C., Collins, A., Cooke,  
503 M., Coolen, S., Haenen, G., Hoberg, A.M., Loft, S., Lunec, J., Olinski, R., Parry, J.,  
504 Pompella, A., Poulsen, H., Verhagen, H., Astley, S.B., 2002. Biomarkers. *Molecular*  
505 *Aspects of Medicine* 23, 101–208.
- 506 Israfi, D.A., Khaizurin, T.A., Syahida, A., Lajis, N.H., Khozirah, S., 2007. Cardamonin  
507 inhibits COX and iNOS expression via inhibition of p65NF-kappaB nuclear  
508 translocation and I-kappa-B phosphorylation in RAW 264.7 macrophage cells.  
509 *Mol. Immunol.* 44, 673–679.
- 510 Itabe, H., Takeshima, E., Iwasaki, H., Kimura, J., Yoshida, Y., Imanaka, T., Takano, T.,  
511 1994. A monoclonal antibody against oxidized lipoprotein recognizes foam cells  
512 in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines  
513 and polypeptides. *J. Biol. Chem.* 269, 15274–15279.
- 514 Iwaki, T., Ishizaki, K., Kinoshita, S., Tanaka, H., Fukunari, A., Tsurufuji, M., Imada, T.,  
515 2007. Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-  
516 induced liver injury in hamsters. *World J. Gastroenterol.* 13, 5003–5008.
- 517 Kadota, S., Tezuka, Y., Prasain, J.K., Ali, M.S., Banskota, A.H., 2003. Novel  
518 diarylheptanoids of *Alpinia blepharocalyx*. *Curr. Top. Med. Chem.* 3, 203–225.
- 519 Kim, M.S., Sweeney, T.R., Shigenaga, J.K., Chui, L.G., Moser, A., Grunfeld, C., Feingold,  
520 K.R., 2007. Tumor necrosis factor and interleukin 1 decrease RXRalpha,  
521 PPARalpha, PPARgamma, LXRA, and the coactivators SRC-1, PGC-1alpha,  
522 and PGC-1beta in liver cells. *Metabolism* 6, 267–279.
- 523 Knopp, R.H., Paramsothy, P., Atkinson, B., Dowdy, A., 2008. Comprehensive lipid  
524 management versus aggressive low-density lipoprotein lowering to reduce  
525 cardiovascular risk. *Am. J. Cardiol.* 101, 48B–57B.
- 526 Kopprasch, S., Pietzsch, J., Kuhlisch, E., Fuecker, K., Temelkova-Kurktschiev, T.,  
527 Hanefeld, M., Kühne, H., Julius, U., Graessler, J., 2002. In vivo evidence for  
528 increased oxidation of circulating LDL in impaired glucose tolerance. *Diabetes*  
529 51, 3102–3106.
- 530 Korantzopoulos, P., Galaris, D., Papaioannides, D., Siogas, K., 2003. The possible role  
531 of oxidative stress in heart failure and the potential of antioxidant intervention.  
532 *Med. Sci. Monit.* 9, 120–125.
- 533 Lee, C.C., Houghton, P., 2005. Cytotoxicity of plants from Malaysia and Thailand  
534 used traditionally to treat cancer. *J. Ethnopharmacol.* 100, 237–243.
- 535 Lin, C.T., Senthil Kumar, K.J., Tseng, Y.H., Wang, Z.J., Pan, M.Y., Xiao, J.H., Chien, S.C.,  
536 Wang, S.Y., 2009. Anti-inflammatory activity of Flavokawain B from *Alpinia*  
537 *pricei* Hayata. *J. Agric. Food Chem.* 57, 6060–6065.
- 538 Lin, L.Y., Peng, C.C., Liang, Y.J., Yeh, W.T., Wang, H.E., Yu, T.H., Peng, R.Y., 2008.  
539 *Alpinia zerumbet* potentially elevates high-density lipoprotein cholesterol level  
540 in hamsters. *J. Agric. Food Chem.* 56, 4435–4443.
- 541 Mead, J.R., Ramji, D.P., 2002. The pivotal role of lipoprotein lipase in atherosclerosis.  
542 *Cardiovasc. Res.* 55, 261–269.
- 543 Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., Evans, R.M., 1998. Oxidized LDL  
544 regulates macrophage gene expression through ligand activation of PPARgamma. *Cell*  
545 93, 229–240.
- 546 Ngo, K.S., Brown, G.D., 1998. Stilbenes, monoterpenes, diarylheptanoids, labdanes,  
547 and chalcones from *Alpinia katsumadai*. *Phytochemistry* 47, 1117–1123.
- 548 Olszanecki, R., Jawieñ, J., Gajda, M., Mateuszuk, L., Gebaska, A., Korabiowska, M.,  
549 Chłopicki, S., Korbut, R., 2005. Effect of curcumin on atherosclerosis in apoE/  
550 LDLR-double knockout mice. *J. Physiol. Pharmacol.* 56, 627–635.
- 551 Plutzky, J., 2000. Peroxisome proliferator-activated receptors in vascular biology  
552 and atherosclerosis: emerging insights for evolving paradigms. *Curr.*  
553 *Atheroscler. Rep.* 2, 327–335.
- 554 Ramirez-Tortosa, M.C., Mesa, M.D., Aguilera, M.C., Quiles, J.L., Baró, L., Ramirez-  
555 Tortosa, C.L., Martinez-Victoria, E., Gil, A., 1999. Oral administration of a  
556 turmeric extract inhibits LDL oxidation and has hypocholesterolemic  
557 effects in rabbits with experimental atherosclerosis. *Atherosclerosis* 147, 371–  
558 378.
- 559 Sawada, M., Matsuo, M., Seki, J., 2002. Inhibition of cholesterol synthesis causes  
560 both hypercholesterolemia and hypocholesterolemia in hamsters. *Biol. Pharm.*  
561 *Bull.* 25, 1577–1582.
- 562 Schild, R.L., Schaiff, W.T., Carlson, M.G., Cronbach, E.G., Nelson, D.M., Sadovsky, Y.,  
563 2002. The activity of PPAR gamma in primary human trophoblasts is enhanced  
564 by oxidized lipids. *J. Clin. Endocrinol. Metab.* 87, 1105–1110.
- 565 Sherman, K.E., 1991. Alanine aminotransferase in clinical practice. A review. *Arch.*  
566 *Intern. Med.* 151, 260–265.
- 567 Shi, G.F., An, L.J., Jiang, B., Guan, S., Bao, Y.M., 2006. *Alpinia protocatechuic acid*  
568 protects against oxidative damage in vitro and reduces oxidative stress in vivo.  
569 *Neurosci. Lett.* 403, 206–210.
- 570 Shin, J.E., Han, M.J., Song, M.C., Baek, N.I., Kim, D.H., 2004. 5-Hydroxy-7-(4'-hydroxy-  
571 3'-methoxyphenyl)-1-phenyl-3-heptanone: a pancreatic lipase inhibitor  
572 isolated from *Alpinia officinarum*. *Biol. Pharm. Bull.* 27, 138–140.
- 573 Slatter, D.A., Bolton, C.H., Bailey, A.J., 2000. The importance of lipid-derived  
574 malondialdehyde in diabetes mellitus. *Diabetologia* 43, 550–557.
- 575 Steinberg, D., 2005. Hypercholesterolemia and inflammation in atherogenesis: two  
576 sides of the same coin. *Mol. Nutr. Food Res.* 49, 995–998.
- 577 Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., Evans, R.M., 1998. PPARgamma  
578 promotes monocyte/macrophage differentiation and uptake of oxidized LDL.  
579 *Cell* 93, 241–252.
- 580 Twickler, T., Dallinga-Thie, G.M., Chapman, M.J., Cohn, J.S., 2005. Remnant  
581 lipoproteins and atherosclerosis. *Curr. Atheroscler. Rep.* 7, 140–147.
- 582 Verhagen, H., Aruoma, O.I., van Delft, J.H., Dragsted, L.O., Ferguson, L.R., Knasmüller,  
583 S., Pool-Zobel, B.L., Poulsen, H.E., Williamson, G., Yannai, S., 2003. The 10 basic  
584 requirements for a scientific paper reporting antioxidant, antimutagenic or  
585 anticarcinogenic potential of test substances in in vitro experiments and animal  
586 studies in vivo. *Food Chem. Toxicol.* 41, 603–610.
- 587 Yang, H.L., Chen, S.C., Chen, C.S., Wang, S.Y., Hseu, Y.C., 2008. *Alpinia pricei* rhizome  
588 extracts induce apoptosis of human carcinoma KB cells via a mitochondria-  
589 dependent apoptotic pathway. *Food Chem. Toxicol.* 46, 3318–3324.
- 590 Wilson, T.A., Nicolosi, R.J., Lawton, C.W., Babiak, J., 1999. Gender differences in  
591 response to hypercholesterolemic diet in hamsters: effects on plasma  
592 lipoprotein cholesterol concentrations and early aortic atherosclerosis.  
593 *Atherosclerosis* 146, 83–91.
- 594 Wilson, T.A., Nicolosi, R.J., Saati, A., Kotyla, T., Kritchevsky, D., 2006.  
595 Conjugated linoleic acid isomers reduce blood cholesterol levels but not  
596 aortic cholesterol accumulation in hypercholesterolemic hamsters. *Lipids* 41,  
597 41–48.
- 598
- 599